Abstract 2328: Targeting angiogenesis: Anti-docking site peptides to Met receptor and nanotechnology

Abstract

Abstract The Met tyrosine kinase receptor is involved in different cell responses during development and pathological conditions. In cancer, Met can promote growth, invasion, angiogenesis and tumor metastasis following the interaction with its ligand, the hepatocyte growth factor (HGF). We decided to develop angiogenesis inhibitors that target the HGF pathway, impairing tumour neo-vascularization and metastatic spreading. We investigated the anti-angiogenic proprieties of a synthetic peptide mimicking the intracellular Met-tail, which was delivered into cells by fusion with the internalization sequences from Antennapedia or HIV-Tat. We are also trying to do peptide delivery by using carbon nanotubes. In order to evaluate the effect of Met-derived inhibitors on angiogenesis, we treated HUVEC with peptides and we evaluated their ability to interfere with HGF-induced proliferation, migration and morphogenesis of endothelial cells in vitro and angiogenesis. Kaposi's sarcoma (KS), the most frequent neoplasia in patients with AIDS, which originates from endothelial origin and is highly vascularized, shows features compatible with the biological properties of HGF. We used KS as tumour model to test the effect of peptides on tumour growth in vivo. We found that the peptides inhibited ligand-dependent endothelial cell proliferation, migration and morphogenesis in vitro and interfered with HGF-dependent downstream signalling. In vivo, the peptides inhibited HGF-induced angiogenesis and Kaposi's sarcoma tumour growth. We also demonstrated that diacylglycerol kinases (DGK) contribute to the malignant phenotype of KS. The data obtained show that the peptides impair angiogenesis triggered by HGF, suggesting the use of anti-docking site compounds as therapeutic agents to interfere with the angiogenesis process. The development of angiogenesis inhibitors and the identification of new intracellular transducers effective in the high vascularised KS cells, open the possibility of a combination therapy that concomitantly interferes with tumour neo-vascularization and the malignant properties of KS. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2328. doi:1538-7445.AM2012-2328